Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 4/20 | 1.00 |
| ▸ | CTSK | P43235 | 3/20 | 1.00 |
| ▸ | CTSL | P07711 | 3/20 | 1.00 |
| ▸ | USP30 | Q70CQ3 | 16/20 | 0.79 |
| ▸ | CTSS | P25774 | 2/20 | 0.76 |
| ▸ | CTSC | P53634 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21324958 | 0.96 | CTSB (0.93) | CTSBCTSKCTSLUSP30CTSS | |
| Cyanamide SCHEMBL6859700 | 0.96 | CTSB (0.92) | CTSBCTSKCTSLUSP30CTSS | |
| SCHEMBL7009469 | 0.92 | CTSB (1.00) | CTSBCTSKCTSLUSP30CTSS | |
| SCHEMBL6858886 | 0.92 | CTSB (1.00) | CTSBCTSKCTSLUSP30CTSS | |
| SCHEMBL23000673 | 0.89 | USP30 (0.87) | CTSBCTSKCTSLUSP30 | |
| SCHEMBL18115475 | 0.89 | USP30 (1.00) | CTSBCTSKCTSLUSP30CTSS | |
| SCHEMBL22068296 | 0.88 | CTSB (0.78) | CTSBCTSKCTSLUSP30CTSS | |
| SCHEMBL21324322 | 0.88 | CTSB (0.77) | CTSBCTSKCTSLUSP30CTSS | |
| SCHEMBL19998580 | 0.86 | CTSB (0.76) | CTSBCTSKCTSLUSP30CTSS | |
| SCHEMBL19998575 | 0.86 | CTSB (0.76) | CTSBCTSKCTSLUSP30CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6835727-B2 | Bone disorders; osteoporosis; rheumatic diseases | MERCK FROSST CANADA & CO. (CA) | 2004-12-28 | — | — | US | claimed |
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2003-12-11 | — | — | US | claimed |
| EP-1272467-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2003-05-07 | — | — | EP | claimed |
| EP-1272467-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2003-01-08 | — | — | EP | claimed |
| WO-2001077073-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-10-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229226-A1 | Cathepsin cysteine protease inhibitors | CTSK, CTSZ, CTSE | CTSB 5/4885CTSK 1/4885CTSL 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.